A carregar...
Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
Non-small cell lung cancer (NSCLC) driven by activating mutations in epidermal growth factor receptor (EGFR) constitutes up to 10% of NSCLC cases. According to the NCCN recommendations, all patients (with the exception of smoking patients with squamous cell lung cancer) should be screened for the pr...
Na minha lista:
| Publicado no: | Contemp Oncol (Pozn) |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Termedia Publishing House
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5701587/ https://ncbi.nlm.nih.gov/pubmed/29180936 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/wo.2017.70116 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|